CS-1003 clinical trials
Also written CS1003.
How each study uses CS-1003 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CS1003
- 2
Studies by the year they started
4 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2018 | 3 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
CS1002 (1) · Ipilimumab (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses CS-1003 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingPhase 3CStone PharmaceuticalsNCT04194775Written as Nofazinlimab (CS1003)+Lenvatinib
- A Study of CS1002 in Subjects with Advanced Solid TumorsCompletedPhase 1CStone PharmaceuticalsNCT03523819Written as CS1003
- A Study of CS1003 in Subjects With Advanced Solid Tumors or LymphomasCompletedPhase 1CStone PharmaceuticalsNCT03809767Written as CS1003 monoclonal antibody
- A Study of CS1003 in Subjects With Advanced Solid TumorsCompletedPhase 1CStone PharmaceuticalsNCT03475251Written as CS1003
Codes
What other systems call CS-1003 · ClinicalTrials.gg INT001705
- MeSH (NLM) C000719047CS-1003Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 42T48Q7A6ONOFAZINLIMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719047 | CS-1003 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 42T48Q7A6O | NOFAZINLIMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.